Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AKB-9778 4% · 1 trial · 2 indications
Change from Baseline in Diurnal Mean IOP (mmHg) at Day 28 in the Study Eye -- ITT Population
| Arm | Type | Description |
|---|---|---|
| AKB-9778 4% QD + Latanoprost | EXPERIMENTAL | • AKB-9778 4% daily (AM) and placebo for ophthalmic solution daily (PM) plus latanoprost daily (PM) for 28 days |
| AKB-9778 4% BID + Latanoprost | EXPERIMENTAL | • AKB-9778 4% twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days |
| Placebo Twice Daily + Latanoprost | PLACEBO_COMPARATOR | • Placebo for AKB-9778 4% ophthalmic solution twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days |
| Name | Type | Description |
|---|---|---|
| Latanoprost ophthalmic solution | DRUG | Latanoprost opthalmic solution to be dosed once daily |
| AKB-9778 4% | DRUG | Razuprotafib opthalmic solution |
| Placebo | DRUG | placebo for razuprotafib opthalmic solution |
Key Inclusion Criteria: * Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is acceptable) * Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP lowerin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |